# A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

> **NCT04236310** · PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 37 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer
- ER-positive Breast Cancer

## Interventions

- **DRUG:** SHR6390
- **DRUG:** Anastrozole
- **DRUG:** Pyrotinib
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT04236310
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-15
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2020-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04236310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04236310, "A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04236310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*